Search Within

Paul K Paik

Formats
  1. Meeting Abstract (168)
  2. Journal Article (83)
  3. Review (4)
  4. Book Section (1)
Groups
  1. Department of Medicine (256)
  2. Solid Tumor Oncology Division (256)
  3. Thoracic Oncology (256)
  4. GSK Faculty (77)
  5. Department of Pathology and Laboratory Medicine (74)
  6. Human Oncology and Pathogenesis Program (55)

More Groups

People
  1. Mark Kris (55)
  2. Marc Ladanyi (47)
  3. Gregory Riely (42)
  4. Natasha Rekhtman (41)
  5. Charles Rudin (40)
  6. Jamie Chaft (33)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (32)
  4. 2022 (39)
  5. 2021 (34)
  6. 2020 (18)

More Years

Publications
  1. Journal of Thoracic Oncology (60)
  2. Journal of Clinical Oncology (49)
  3. Annals of Oncology (34)
  4. Clinical Cancer Research (12)
  5. International Journal of Radiation Oncology, Biology, Physics (11)
  6. Clinical Lung Cancer (6)

More Publications

Publishers
  1. Elsevier Inc. (81)
  2. American Society of Clinical Oncology (56)
  3. Oxford University Press (38)
  4. American Association for Cancer Research (22)
  5. Wiley Blackwell (12)
  6. Nature Publishing Group (11)

More Publishers

Results (256)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 trial of bortezomib in KRAS G12D mutant lung cancers
    Meeting Abstract

    Riely, G. J.; Litvak, A.; Rekhtman, N.; Pietanza, M. C.; Chaft, J. E.; Woo, K.; Paik, P.; Miller, V.; Kris, M. G.; Rodriguez, K.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • FP1039/GSK3052230 with chemotherapy in patients with fibroblast growth factor (FGF) pathway deregulated squamous NSCLC or MPM
    Meeting Abstract

    Garrido, P.; Delgado, I.; Felip, E.; Domine, M.; Paik, P.; Trigo, J.; Schellens, J.; Gadgeel, S.; Kindler, H. L.; Lara, P. Jr; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • A phase 1 study of erlotinib and ruxolitinib in patients with EGFR-mutant lung cancers and acquired resistance to erlotinib therapy
    Meeting Abstract

    Yu, H.; Perez, L. A.; Sima, C. S.; Li, B. T.; Smith-Marrone, S.; Iqbal, A.; Paik, P.; Drilon, A.; Kris, M. G.; Bromberg, J.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Longer-term follow-up of a phase 2 study (CheckMate 063) of nivolumab in patients with advanced, refractory squamous non-small cell lung cancer
    Meeting Abstract

    Horn, L.; Rizvi, N. A.; Mazières, J.; Planchard, D.; Stinchcombe, T. E.; Dy, G. K.; Antonia, S. J.; Léna, H.; Minenza, E.; Mennecier, B.; more...
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Response to MET inhibitors in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping
    Meeting Abstract

    Paik, P.; Drilon, A.; Yu, H.; Rekhtman, N.; Borsu, L.; Ginsberg, M.; Berger, M.; Ladanyi, M.; Rudin, C. M.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Targeting gene amplification in squamous cancer
    Meeting Abstract

    Paik, P.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Longer-term follow-up of a phase 2 study (Checkmate 063) of nivolumab in patients with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Horn, L.; Rizvi, N.; Mazieres, J.; Planchard, D.; Stinchcombe, T. E.; Dy, G. K.; Antonia, S. J.; Lena, H.; Minenza, E.; Mennecier, B.; more...
    Asia-Pacific Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gettinger, S. N.; Horn, L.; Ramalingam, S. S.; Spigel, D. R.; Paz-Ares, L.; Paik, P.; Reck, M.; Reckamp, K.; Mazieres, J.; Stinchcombe, T.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS)
    Meeting Abstract

    Pietanza, M. C.; Won, H. H.; Rekhtman, N.; Wang, L.; Travis, W. D.; Krug, L. M.; Varghese, A. M.; Paik, P. K.; Riely, G. J.; Zakowski, M. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping
    Meeting Abstract

    Paik, P. K.; Drilon, A. E.; Yu, H. A.; Krug, L. M.; Rekhtman, N.; Borsu, L.; Ginsberg, M. S.; Berger, M. F.; Ladanyi, M.; Rudin, C. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save